DDInter626 DDInter210
Elbasvir is a direct-acting antiviral medication used as part of combination therapy to treat chronic hepatitis C, an infectious liver disease caused by infection with hepatitis C virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, affecting 72% of all chronic HCV patients. Treatment options for chronic hepatitis C have advanced significantly since 2011, with the development of direct-acting antivirals (DAAs) such as elbasvir. Elbasvir is an inhibitor of NS5A, a protein essential for viral replication and virion assembly.[synthesis] The barrier to the development of resistance to NS5A inhibitors is lower than that of NS5B inhibitors, another class of DAAs. Substitutions at amino acid positions 28, 30, 31, or 93 are known to confer resistance to elbasvir. Despite this
Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with the BRAF V600E or V600K mutations, as detected by an FDA-approved test.
Binimetinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Delavirdine
Binimetinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Troleandomycin
Binimetinib {u} may lead to a major life threatening interaction when taken with {v} Ramucirumab
Binimetinib {u} may lead to a major life threatening interaction when taken with {v} Zanubrutinib
Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine
Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Binimetinib may lead to a major life threatening interaction when taken with Ramucirumab
Binimetinib may lead to a major life threatening interaction when taken with Zanubrutinib